By Kelly Cloonan
Shares of Portage Biotech climbed after the company reported confirmatory data for its PORT-7 treatment of mesothelioma, supporting plans for a human trial.
The stock rose 21% to $10.23 Monday. Shares have more than doubled over the past 12 months.
The clinical stage immuno-oncology company said Monday its PORT-7, a selective adenosine A2B receptor inhibitor, demonstrated superior single agent activity compared with treatment with single agent anti-PD1 antibody in a murine model.
Combining both PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone, showing favorable immune response and increases in immune effector cells for mice in the trial, the company said.
The treatment is targeted at mesothelioma, an aggressive cancer with limited treatment options.
Portage is now making preparations to begin a first-in-human clinical trial with PORT-7, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 28, 2025 13:20 ET (17:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。